Global Multiple Sclerosis Drugs Market Research Report 2021

Multiple sclerosis (MS) is a demyelinating disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged. This damage disrupts the ability of parts of the nervous system to communicate, resulting in a range of signs and symptoms, including physical, mental, and sometimes psychiatric problems.

The global Multiple Sclerosis Drugs market was valued at US$ 14610 million in 2020 and is expected to reach US$ 21240 million by the end of 2027, growing at a CAGR of 5.0% during 2021-2027.
This report focuses on Multiple Sclerosis Drugs volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Multiple Sclerosis Drugs market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.

Global Multiple Sclerosis Drugs Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type
Injectable Medications
Oral Medications
Others

Segment by Application
Adults
Children

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E

By Company
Biogen
Sanofi
Novartis
Teva
Merck KGaA
Bayer
ACORDA
Mallinckrodt